Drug updated on 11/14/2023
|Tablet (oral: 20 mg 40 mg, 50 mg, 60 mg)
|Nuclear export inhibitors
| Ongoing and
- Indicated in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
- Indicated in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody.
- Indicated for the treatment of adult patients with relapsed or refractory diffuse large B‐cell lymphoma (DLBCL), not otherwise specified, including DLBC arising from follicular lymphoma, after at least 2 lines of systemic therapy.
Product Monograph / Prescribing Information
|Xpovio (selinexor) Prescribing Information.
|Karyopharm Therapeutics Inc., Newton, MA
Systematic Reviews / Meta-Analyses
|Clinical and pharmacoeconomic combined report: selinexor (Xpovio).
|Efficacy and safety of selinexor-based regimens for relapsed/refractory multiple myeloma: a systematic review of literature.
|Annals of Hematology
Clinical Practice Guidelines
|Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
|Annals of Oncology